Prnewswireยท2025-07-22 12:42Core Insights - NeuroSense Therapeutics is a late-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, particularly ALS [12] - The company is set to unveil new insights regarding its investigational therapy PrimeC and its regulatory progress in Canada during a live broadcast event hosted by Aaron Lazar [1][2] Company Overview - NeuroSense Therapeutics is dedicated to discovering and developing therapies for neurodegenerative diseases, including ALS, Alzheimer's, and Parkinson's, which represent significant unmet medical needs [12] - The company employs a strategy of developing combined therapies that target multiple pathways associated with these diseases [12] Product Development - PrimeC, NeuroSense's lead drug candidate, is an extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, aimed at addressing key mechanisms of ALS [11] - The Phase 2a clinical trial for PrimeC has met safety and efficacy endpoints, showing potential in reducing functional and respiratory deterioration and demonstrating biological activity through significant changes in ALS-related biomarkers [11] Regulatory Milestones - PrimeC has received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency, indicating its potential to address a rare disease with limited treatment options [11] - The upcoming live event will discuss NeuroSense's regulatory path in Canada and the latest developments regarding its binding term sheet with a pharmaceutical partner [2]